Business
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site specializing in allergy studies, marking a key milestone toward the initiation of its clinical program for the NASARIXTM (PL-14) Allergy Blocker. The clinical site, locate
About this update from Polyrizon Ltd.
[{"type":"text","content":"Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site specializing in allergy studies, marking a key milestone toward the initiation of its clinical program for the NASARIXTM (PL-14) Allergy Blocker.","length":474,"tagName":"p"},{"type":"text","content":"The clinical site, located in Texas, will serve as the first participating center in Polyrizon’s planned multi-center study evaluating the safety, tolerability, and efficacy of the NASARIXTM Allergy Blocker in patients with seasonal allergic rhinitis.","length":251,"tagName":"p"},{"type":"text","content":"The clinical study, titled “Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis”, will assess the performance of Polyrizon’s investigational nasal spray designed to create a protective barrier against airborne allergens.","length":315,"tagName":"p"},{"type":"text","content":"“This agreement represents an important step in transitioning NASARIXTM from development stage into potential clinical validation,” said Tomer Izraeli, CEO of Polyrizon. “We are pleased to collaborate with an experienced clinical team as we advance toward initiating our first-in-human clinical study.”","length":302,"tagName":"p"},{"type":"text","content":"The study is planned as a multi-center trial, with additional clinical sites expected to be added in the coming months. The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting Polyrizon’s broader regulatory strategy.","length":311,"tagName":"p"},{"type":"text","content":"NASARIXTM is an investigational intranasal formulation designed to provide a non-pharmacological barrier against allergens, with the goal of preventing allergic reactions at the point of entry.","length":193,"tagName":"p"},{"type":"text","content":"About Polyrizon","length":15,"tagName":"p"},{"type":"text","content":"Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogel...